Progyny stock reports 5.3 percent revenue growth in Q2

Published on 09/25/2026 at 10:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Progyny stock posted diluted EPS of USD 0.34 in Q2 2026, up from USD 0.19 a year earlier. Bank of America disclosed 598,815 shares on September 25, 2026.

PGNY, US74340E1038, Illustration mit AI erstellt.

Progyny stock (ISIN US74340E1038) stood at USD 25.97 on Nasdaq on September 24, 2026, while second-quarter revenue reached USD 350.5 million, up 5.3 percent year over year. The current market angle is institutional ownership: MarketBeat reported on September 25, 2026 that Bank of America acquired 598,815 shares during the second quarter.

Revenue growth reaches 5.3 percent

According to The Globe and Mail in its September 23, 2026 transcript of Progyny's Q2 2026 earnings call, revenue increased from USD 333.0 million in the prior-year quarter to USD 350.5 million. Fertility benefit revenue rose 7.6 percent to USD 230.2 million, while pharmacy benefit revenue increased 1.2 percent to USD 120.3 million.

The earnings mix matters because fertility benefits remain the larger revenue contributor. The pharmacy business grew more slowly, making client additions and covered lives central to the company's reported expansion.

Profit improves against prior year

Progyny's Q2 net income was USD 28.1 million, compared with USD 17.1 million in the prior-year period, while diluted EPS reached USD 0.34 versus USD 0.19. The combination of 5.3 percent revenue growth and higher earnings points to operating leverage in the latest reported quarter.

Management projected third-quarter revenue of USD 335 million to USD 345 million, according to the same September 23, 2026 transcript. The range implies a sequential decline from Q2 revenue of USD 350.5 million and reflects the seasonal pattern described in the call.

Stock remains below yearly high

Progyny stock traded at USD 25.97 on Nasdaq on September 24, 2026, with a daily gain of 0.54 percent. Its market capitalization was USD 2,034,291,649, and the 52-week range was USD 16.10 to USD 33.06, placing the share price 21.4 percent below the yearly high.